ライフサイエンスコーパス: autoimmune disease

1 of self-reactive effector T cells to induce autoimmune disease.

2 atherosclerosis, cytokine storm, and chronic autoimmune disease.

3 , which is implicated in the pathogenesis of autoimmune disease.

4 by the PTPN22 R620W variant associated with autoimmune disease.

5 ic sclerosis (SSc) is a complex, multiorgan, autoimmune disease.

6 but also suffer greater immunopathology and autoimmune disease.

7 ntly effective in models of inflammatory and autoimmune disease.

8 e immune tolerance in other animal models of autoimmune disease.

9 Approximately 30% of ICL patients develop autoimmune disease.

10 sis of iTTP and with extension for any other autoimmune disease.

11 O mice that develop early- versus late-stage autoimmune disease.

12 B cells co-occur in nearly all patients with autoimmune disease.

13 tolerance in the setting of inflammation and autoimmune disease.

14 P1 variant associated with increased risk of autoimmune disease.

15 ts for T(reg) immunotherapies for cancer and autoimmune disease.

16 also prominent effectors of inflammation and autoimmune disease.

17 vely blocked the course of a T cell-mediated autoimmune disease.

18 d contribute to the molecular etiology of an autoimmune disease.

19 nces in subclass balance are associated with autoimmune disease.

20 in patients on immunomodulatory therapy for autoimmune disease.

21 t for restoring tissue homeostasis in ocular autoimmune disease.

22 ipid vaccination or infection during chronic autoimmune disease.

23 he drivers of systemic abnormalities such as autoimmune disease.

24 ties involving the cardiovascular system and autoimmune disease.

25 gulation may contribute to susceptibility to autoimmune disease.

26 reased in mice and humans with infections or autoimmune diseases.

27 e implicated in the pathogenesis of numerous autoimmune diseases.

28 underpin anti-microbial defenses and certain autoimmune diseases.

29 n important role in several inflammatory and autoimmune diseases.

30 deficiency has been associated with various autoimmune diseases.

31 ucial role in the progression to established autoimmune diseases.

32 t susceptibility to infectious, allergic and autoimmune diseases.

33 ontexts of viral infection, malignancies and autoimmune diseases.

34 g the design of more specific treatments for autoimmune diseases.

35 ntry into tissues is an effective therapy in autoimmune diseases.

36 plexes that likely play a pathogenic role in autoimmune diseases.

37 antigens found in APS1 extend to more common autoimmune diseases.

38 plays a pivotal role in the pathogenesis of autoimmune diseases.

39 for preventing the symptoms of allergic and autoimmune diseases.

40 nsible for a broad array of inflammatory and autoimmune diseases.

41 receptor associated with the pathogenesis of autoimmune diseases.

42 on of vaccine efficacy and the treatment for autoimmune diseases.

43 s for treating infectious, inflammatory, and autoimmune diseases.

44 ith bleeding disorders, immunodeficiency, or autoimmune diseases.

45 es), resulting in organ-specific or systemic autoimmune diseases.

46 d systemic disorders, such as malignancy and autoimmune diseases.

47 chronic inflammatory conditions, cancer, and autoimmune diseases.

48 potential therapeutic approach for managing autoimmune diseases.

49 metabolic disorders to neurodegeneration and autoimmune diseases.

50 G are increasingly used for the treatment of autoimmune diseases.

51 otein citrullination plays a role in several autoimmune diseases.

52 h potential use in transplantation and other autoimmune diseases.

53 ed in anticancer immunity and also in T cell autoimmune diseases.

54 mRNA, which is associated with inflammatory autoimmune diseases.

55 considered an attractive target for treating autoimmune diseases.

56 cal challenge for understanding and treating autoimmune diseases.

57 pment of new therapeutic agents for treating autoimmune diseases.

58 oot cause of self-Ag-specific T cell-induced autoimmune diseases.

59 protein function and has been implicated in autoimmune diseases.

60 c target for the cutaneous manifestations of autoimmune diseases.

61 late the immune system and modulate multiple autoimmune diseases.

62 ghts into the pathoetiology and treatment of autoimmune diseases.

63 ) organ transplantation and the treatment of autoimmune diseases.

64 chanisms that usually guard the host against autoimmune diseases.

65 IL-17A is a therapeutic target in many autoimmune diseases.

66 is a promising target for treating a host of autoimmune diseases.

67 STAT3 in T cell prevents development of CNS autoimmune diseases.

68 ncluding neurological disorders, cancer, and autoimmune diseases.

69 ally involved in the pathogenesis of several autoimmune diseases.

70 k for the development of several cancers and autoimmune diseases.

71 vel approaches to treat chronic inflammatory autoimmune diseases.

72 cer-promoting inflammation in TNBC and other autoimmune diseases.

73 ciation of GPS with immune dysregulation and autoimmune diseases.

74 has been associated with various cancers and autoimmune diseases.

75 ails complications that bear similarities to autoimmune diseases.

76 c induction of antigen-specific tolerance in autoimmune diseases.

77 or cells, which are commonly dysregulated in autoimmune diseases.

78 latory subsets has met success in mitigating autoimmune diseases.

79 e search for effective treatment of systemic autoimmune diseases.

80 ssue degradation in chronic inflammatory and autoimmune diseases.

81 iological mechanisms involved in more common autoimmune diseases.

82 s NR to more effectively treat patients with autoimmune diseases.

83 might be problematic, such as in people with autoimmune diseases.

84 hways have been linked to the development of autoimmune diseases.

85 potential therapeutic agents for cancers and autoimmune diseases.

86 in a much wider variety of antibody-mediated autoimmune diseases.

87 c obstructive pulmonary disease, and various autoimmune diseases.

88 evance to the treatment of B cell-associated autoimmune diseases.

89 r immunotherapy of malignant, infectious and autoimmune diseases.

90 process is an emerging strategy for managing autoimmune diseases.

91 rs to provide a mechanistic understanding of autoimmune diseases.

92 d suppressing the development or severity of autoimmune diseases.

93 s, including infections and inflammatory and autoimmune diseases(1,2,5).

94 esvirus reactivation and subsequent onset of autoimmune diseases(1-4).

95 r (49.9%), followed by malignancies (28.0%), autoimmune diseases (12.1%), unknown triggers (9.4%), an

96 e endolysosomal TLR machinery also linked to autoimmune disease(4,6-9).

97 Among patients with concomitant autoimmune diseases, a lower proportion of patients in t

98 cine responsiveness and mitigate undesirable autoimmune disease activity.

99 lity complex II-associated susceptibility to autoimmune diseases acuminates in a proinflammatory IgG

100 ted a significant association with premorbid autoimmune diseases (adjusted OR 1.34 [1.14-1.58] and 1.

101 igher significant association with premorbid autoimmune diseases (adjusted OR 1.39 [1.28-1.50]).

102 ted a significant association with premorbid autoimmune diseases (adjusted OR 2.02 [1.72-2.49] and 1.

103 R) for SCAD among patients with a history of autoimmune disease, adjusting for race and body mass ind

104 SAMHD1 mutations are associated with the autoimmune disease Aicardi-Goutieres syndrome and hyperm

105 and Takayasu arteritis (TA) is an even rarer autoimmune disease (AID), both of which present with inf

106 The pathogenesis of autoimmune diseases (AIDs) is not only attributed to gen

107 treatment strategy being applied to cancer, autoimmune diseases, allergies, and transplantation.

108 full analysis set stratified by concomitant autoimmune diseases, among patients without concomitant

109 ubiquitin ligase with critical functions in autoimmune disease and antiviral immunity.

110 lead to more effective T(reg) therapies for autoimmune disease and cancer.

111 icient mice (IL-2Ralpha-KO) develop systemic autoimmune disease and die from severe anemia between 18

112 h genes found in GWAS of MDD disease status, autoimmune disease and inflammation, and co-localized wi

113 es clinical and genetic associations between autoimmune disease and PD, impaired cellular and humoral

114 d leukocyte counts and increased presence of autoimmune disease and positive autoantibodies.

115 5 is being actively pursued for treatment of autoimmune disease and prevention of allograft rejection

116 mmune tolerance that are critical to prevent autoimmune disease and promote an anti-inflammatory tiss

117 ed strategies aimed at lowering the risk for autoimmune disease and underscoring the need to consider

118 t at an IVIg mechanism of action in treating autoimmune diseases and allosensitization by acceleratin

119 F-kappaB transcription factor c-Rel to human autoimmune diseases and B cell lymphomas, respectively.

120 xt of peripheral tolerance, transplantation, autoimmune diseases and cancer.

121 artery dissection (SCAD) is associated with autoimmune diseases and causes 2% to 4% of acute coronar

122 Autoimmune diseases and celiac disease were excluded.

123 r suppressing pathologic immune responses in autoimmune diseases and graft rejection.

124 Th17 cells are critical drivers of autoimmune diseases and immunopathology.

125 BAFF contributes to the development of some autoimmune diseases and malignancies.

126 as important implications in T(H)17-mediated autoimmune diseases and neutrophil-dependent asthma.

127 ogy of i35-Breg cell, i35-Breg therapies for autoimmune diseases and potential therapeutic strategies

128 ptive immune cells associated with viral and autoimmune diseases and targeted by pathogens for immune

129 sence of extraocular involvement, history of autoimmune disease, and durations of follow-up.

130 ombocytopenia, eczema, recurrent infections, autoimmune disease, and malignancy.

131 disorders, including cardiovascular disease, autoimmune disease, and menopausal symptoms, that affect

132 count of at least 150 cells per microliter, autoimmune disease, and other allergic and immunologic d

133 s pathologies such as neurological diseases, autoimmune diseases, and cancers.

134 s an important role in cancer metastasis, in autoimmune diseases, and during stem cell-based repair p

135 treatment of subsets of lymphomas as well as autoimmune diseases, and there is a need for suitable co

136 range of infections, antitumor surveillance, autoimmune diseases, and tissue homeostasis.

137 tegy with minimum toxicity for Th17-mediated autoimmune diseases, and, more generally, that metabolic

138 roliter aOR = 1.54 [95% CI = 1.21-1.97]; and autoimmune disease aOR = 1.68 [95% CI = 1.36-2.07]).

139 establish that crucial SNPs linked to autoimmune disease are enriched in DNA regions of CpG de

140 iated genetic susceptibility translates into autoimmune disease are not fully understood.

141 Antibody-mediated autoimmune diseases are a major health burden.

142 Autoimmune diseases are a result of the immune system be

143 Autoimmune diseases are chronic inflammatory diseases as

144 Tissue-specific autoimmune diseases are driven by activation of diverse

145 Psoriasis is a T helper type 17 autoimmune disease associated with an increased risk car

146 genesis is noninflammatory and screening for autoimmune diseases based on SCAD alone is not warranted

147 ew criteria for comprehensive diagnostics of autoimmune diseases, based not only on traditional measu

148 e treatment of hematological malignancies or autoimmune disease but may be responsible for a secondar

149 Pathogenic autoantibodies arise in many autoimmune diseases, but it is not understood how the ce

150 of depression is higher in individuals with autoimmune diseases, but the mechanisms underlying the o

151 can contribute to the development of various autoimmune diseases, but the regulation of serum IgA eff

152 ntify a preventive approach for the onset of autoimmune disease by specifically targeting impaired in

153 ee biosensor is developed for diagnostics of autoimmune diseases by highly sensitive measuring in hum

154 i35-Bregs suppress central nervous system autoimmune diseases by inducing infectious tolerance whe

155 ng the association between CRS and premorbid autoimmune diseases by using the National Health Insuran

156 The study of familial autoimmune diseases can reveal pathophysiological mechan

157 and several of the aaRSs have been linked to autoimmune diseases, cancer, and neurological disorders.

158 a central nervous system (CNS) inflammatory autoimmune disease caused by antibodies against aquapori

159 Myasthenia gravis (MG) is a neuromuscular, autoimmune disease caused by autoantibodies that target

160 ) is a debilitating and painful inflammatory autoimmune disease characterised by the accumulation of

161 ic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antinuclear antibodi

162 Multiple sclerosis (MS) is an autoimmune disease characterized by attack on oligodendr

163 disorders (NMOSD) are a type of neurological autoimmune disease characterized by attacks of CNS infla

164 rimary Sjogren's syndrome (pSS) is a complex autoimmune disease characterized by dysfunction of secre

165 Multiple sclerosis (MS) is an autoimmune disease characterized by infiltration of peri

166 clerosis (SSc) is a clinically heterogeneous autoimmune disease characterized by mutually exclusive a

167 Type 1 diabetes is an autoimmune disease characterized by progressive loss of

168 ematosus (SLE) is a clinically heterogeneous autoimmune disease characterized by the development of a

169 upus Erythematosus (SLE) is the prototype of autoimmune diseases, characterized by extensive gene exp

170 Autoimmune diseases comprise a spectrum of illnesses and

171 2 inhibitor provides an opportunity to treat autoimmune diseases delivering a potentially differentia

172 Screening of more than 200 patients with autoimmune disease demonstrated that the prevalence of p

173 Yet, an interesting contrast exists with autoimmune disease development, wherein diminishing path

174 creases autoreactivity and susceptibility to autoimmune disease development.

175 in VHL in their T cells were resistant to an autoimmune disease, experimental autoimmune encephalomye

176 the targeting of co-stimulatory molecules in autoimmune diseases, focusing in particular on agents di

177 This review is focused on the field of autoimmune disease functional genomics with a particular

178 ficant association between CRS and premorbid autoimmune diseases has been identified.

179 The nature of autoantigens that trigger autoimmune diseases has been much discussed, but direct

180 genetic loci and increased susceptibility to autoimmune disease have been well characterized, however

181 ich PRMT5 modulates Th cell polarization and autoimmune disease have not yet been elucidated.

182 Treatment options for autoimmune diseases have increased over the past several

183 Autoimmune disease history came from a validated, code-b

184 s (CRS) is associated with prior presence of autoimmune diseases; however, large-scale population-bas

185 with rheumatoid arthritis and other chronic autoimmune diseases; however, TNFalpha has proven to be

186 The observed persistent, elevated risks for autoimmune diseases, immune deficiencies, and infectious

187 lls, played a key role in the development of autoimmune disease in the central nervous system.

188 Tollip(-/-) also ameliorates STING-mediated autoimmune disease in Trex1(-/-) mice.

189 Myasthenia gravis (MG) is an autoimmune disease in which Abs target neuromuscular jun

190 Type 1 diabetes (T1D) is a T cell-mediated autoimmune disease in which the insulin-producing beta c

191 ent induces T cell apoptosis and ameliorates autoimmune diseases in an exogenously modulated manner,

192 ) fimbriae from Escherichia coli can inhibit autoimmune diseases in murine models by inducing bystand

193 of endosomal TLR7 and TLR8 occurs in several autoimmune diseases, in particular systemic lupus erythe

194 rs play pathogenetic roles in organ-specific autoimmune diseases including celiac disease.

195 IL-23 promotes autoimmune disease, including Th17 CD4 T cell developmen

196 en in the short term, therapeutic target for autoimmune diseases, including ankylosing spondylitis.

197 responses underlie multiple inflammatory and autoimmune diseases, including autoimmune uveitis and it

198 een linked to several infectious diseases or autoimmune diseases, including candidemia and multiple s

199 an unmet clinical need for the treatment of autoimmune diseases, including multiple sclerosis (MS).

200 A-II), at a susceptibility locus for several autoimmune diseases, including multiple sclerosis (MS).

201 The effectiveness of FcRn inhibitors in autoimmune diseases, including myasthenia gravis and imm

202 e also well documented in a variety of human autoimmune diseases, including relapsing-remitting multi

203 A common feature of autoimmune diseases, including systemic lupus erythemato

204 to promote immune tolerance in patients with autoimmune diseases, including type 1 diabetes.

205 LCV has been associated with autoimmune diseases, infections, specific drugs (levoflo

206 tosis with polyangiitis (GPA) is an uncommon autoimmune disease involving multiple organs including e

207 activation during pregnancy via infection or autoimmune disease is a risk factor for neuropsychiatric

208 at the dysregulation of the immune system in autoimmune diseases is associated with a skewing of the

209 rent autoimmune adverse events and classical autoimmune diseases is presently unknown.

210 lex (MHC), which is associated with risk for autoimmune diseases, is also associated with risk for de

211 g recognition of the importance of GM-CSF in autoimmune disease, it remains unclear how GM-CSF is reg

212 erences suggesting distinct mechanisms drive autoimmune disease kinetics.

213 esents a major obstacle in understanding how autoimmune diseases like multiple sclerosis (MS) contrib

214 the potential of PAD inhibition for treating autoimmune diseases like type 1 diabetes.

215 oid arthritis (RA) is a chronic inflammatory autoimmune disease linked to oxidative stress, which is

216 Variation in the risk and severity of many autoimmune diseases, malignancies and infections is stro

217 hibitors have provided into FcRn biology and autoimmune disease mechanisms, allowing fact-based specu

218 Our findings were validated in two autoimmune disease models by demonstrating that lack of

219 adaptive immune response or, in the case of autoimmune diseases, molecules that are part of healthy

220 e would explain the increase of allergic and autoimmune diseases observed over the past decades in hi

221 Autoimmune disease occurred in 13 (11%) cases with SCAD

222 Type 1 diabetes (T1D) is an autoimmune disease of insulin-producing beta-cells.

223 Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS),

224 Multiple sclerosis (MS) is a demyelinating, autoimmune disease of the central nervous system.

225 Multiple sclerosis (MS) - an autoimmune disease of the CNS - increases transcriptiona

226 Multiple sclerosis (MS) is a chronic autoimmune disease of the CNS that is characterized by d

227 Vitiligo is an autoimmune disease of the skin that targets pigment-prod

228 ular mechanism contributing to the polygenic autoimmune diseases of systemic lupus erythematosus and

229 erstanding the role played by lymphocytes in autoimmune diseases of the central nervous system.

230 oneuropathy (CIDP) consists of a spectrum of autoimmune diseases of the peripheral nerves, causing we

231 e when used for approved indications such as autoimmune disease or malaria, the safety and benefit of

232 Jaundice was investigated and infections, autoimmune diseases or drugs adverse reactions, were exc

233 prevent inappropriate secretion of IFN-I in autoimmune diseases or promote IFN-I secretion during vi

234 c antibodies and their effector functions in autoimmune diseases or use of B cell/plasma cell-directe

235 tio [OR], 6.30; P = .020), family history of autoimmune disease (OR, 5.12; P = .002), extra-intestina

236 major role in the genetic susceptibility to autoimmune diseases, or C4 haplotypes, which are strongl

237 We then evaluated autoimmune disease parameters, kidney disease, and respo

238 association studies, relationships to other autoimmune diseases, polygenic architecture of vitiligo

239 ntly inherited predisposition to early onset autoimmune diseases related to cytokine hypersensitivity

240 pMHCII-based nanomedicines displaying liver autoimmune disease-relevant yet ubiquitously expressed a

241 The ability of the immune system to avoid autoimmune disease relies on tolerization of thymocytes

242 to IL-1beta production seen in T cell-driven autoimmune diseases remains unclear.

243 therapy, as being able to ameliorate various autoimmune diseases, researchers have been investigating

244 nuclease 1 (TREX1) cause a spectrum of human autoimmune diseases resembling systemic lupus erythemato

245 Type 1 diabetes is an autoimmune disease resulting in severely impaired insuli

246 Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and

247 mmune cells with highly selective effects on autoimmune disease risk at the cell-subtype level.

248 are key biomarkers in clinical diagnosis of autoimmune diseases routinely detected by enzyme-linked

249 ncephalitis, mirroring the susceptibility to autoimmune diseases seen in people with C9-ALS/FTD.

250 titatively or qualitatively to the patients' autoimmune disease status.

251 into two subgroups according to concomitant autoimmune disease status.

252 also represent an important defense against autoimmune diseases such as MS.

253 d a new mechanism underlying B cell-mediated autoimmune diseases such as MS.

254 nges in the immune system, especially during autoimmune diseases such as Multiple Sclerosis (MS).

255 ys an important role in chronic inflammatory autoimmune diseases such as multiple sclerosis and rheum

256 In autoimmune diseases such as multiple sclerosis, the TCR

257 Th17 cell differentiation is associated with autoimmune diseases such as multiple sclerosis, which ha

258 They are clinically beneficial in autoimmune diseases such as multiple sclerosis.

259 ent protective factor for the development of autoimmune diseases such as rheumatoid arthritis (RA).

260 odies cause inflammation and organ damage in autoimmune diseases such as systemic lupus erythematosus

261 However, their role in autoimmune diseases such as systemic lupus erythematosus

262 play important roles in the pathogenesis of autoimmune diseases (such as arthritis, multiple scleros

263 Often, irAEs resemble spontaneous autoimmune diseases, such as inflammatory bowel disease,

264 ty that they can be beneficial in countering autoimmune diseases, such as type 1 diabetes.

265 and the accelerated atherosclerosis in many autoimmune diseases suggest that targeting inflammation

266 ng autoantigen-experienced CD4+ T cells into autoimmune disease-suppressing T regulatory type 1 (TR1)

267 the most severe organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE).

268 The autoimmune disease systemic sclerosis (SSc) causes micro

269 For instance, the autoimmune diseases systemic lupus erythematosus (SLE) a

270 of ill-defined central nervous system (CNS) autoimmune diseases termed autoimmune encephalitides (AE

271 Systemic scleroderma (SSc) is an autoimmune disease that affects over 2.5 million people

272 Type 1 diabetes (T1D)-an autoimmune disease that destroys the pancreatic islets,

273 Rheumatoid arthritis is a chronic autoimmune disease that leads to destruction of joint ti

274 tissue disease (MCTD) is a rare and complex autoimmune disease that presents mixed features with oth

275 Graves' disease (GD) is an autoimmune disease that primarily affects the thyroid gl

276 titis (AIH) has been recognized as a type of autoimmune disease that responds to corticosteroid.

277 hy individuals and in patients with systemic autoimmune diseases that affect the kidney will also hel

278 st high salt diets have been shown to worsen autoimmune disease, the immunological consequences of cl

279 cer, asthma, allergy, neurodegeneration, and autoimmune diseases they have gained attention as target

280 diseases, among patients without concomitant autoimmune diseases, three (9%) of 34 patients in the to

281 variant (CD32aH) is strongly linked to human autoimmune diseases through unclear mechanisms.

282 tudy determined the association of SCAD with autoimmune diseases, together with incidence and recurre

283 ergoing clinical trials for the treatment of autoimmune diseases, transplant rejection and graft-vers

284 The autoimmune disease type 1 diabetes is characterized by e

285 clear antibodies (ANAs) are detected in many autoimmune diseases, up to 20% of healthy women are ANA-

286 nt of at least 150 cells per microliter, and autoimmune disease were associated with frequent AECRS w

287 ale sex, and a history of hypothyroidism and autoimmune disease were associated with increased risks

288 Even after adjustment, autoimmune diseases were not associated with SCAD (OR: 0

289 nt of at least 150 cells per microliter, and autoimmune disease, were evaluated for associations betw

290 rythematosus (SLE) is a multisystem, chronic autoimmune disease where treatment varies by patient and

291 ctors play a key role in the pathogenesis of autoimmune diseases, whereas the disease-causing variant

292 e types of chronic inflammation ranging from autoimmune disease, which attacks specific tissues, to a

293 and accuracy of our genetic understanding of autoimmune diseases will undoubtedly be helpful, meeting

294 Neuromyelitis Optica (NMO) is an autoimmune disease with a higher prevalence in non-Europ

295 ks HLA alleles associated with high risk for autoimmune disease with ICI-induced T1D and colitis.

296 etagenomics have associated inflammatory and autoimmune diseases with alterations in fungal and viral

297 rimary Sjogren's syndrome (pSS) is a chronic autoimmune disease, with only palliative treatments avai

298 tribution of each major metabolic pathway to autoimmune diseases, with a focus on systemic lupus eryt

299 apted from the literature describing primary autoimmune diseases, without taking into consideration t

300 lytic subunit (DNA-PKcs) are associated with autoimmune diseases, yet how DNA-PK deficiency leads to